Moffitt Imaging Biomarker VAlidation Center

莫菲特成像生物标志物验证中心

• 批准号: 8996954
• 负责人: Robert J. Gillies
• 金额: $ 70.7万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8996954
• 关键词: Algorithms; Biological Markers; Breast; Breast Cancer Detection; Calibration; Cancer Intervention; Classification; Cohort Studies; Collaborations; Collection; Data; Data Collection; Data Set; Databases; Diagnostic; Diagnostic radiologic examination; Differential Diagnosis; Digital Breast Tomosynthesis; Digital Mammography; Early Detection Research Network; Early Diagnosis; Florida; Funding; Goals; Health; Image; Image Analysis; Individual; Lung; Malignant Neoplasms; Measurement; Methods; Modeling; Nodule; Nomograms; Pathway Analysis; Patients; Resolution; Resource Sharing; Resources; Risk; Risk Assessment; Risk Factors; Screening for cancer; Specimen; Structure; Subgroup; Target Populations; Testing; Texture; Time; Translations; Validation; Variant; Work; X-Ray Computed Tomography; base; breast imaging; cancer diagnosis; cancer imaging; cancer risk; case control; clinical application; clinical risk; cohort; high risk; image processing; imaging biomarker; improved; low-dose spiral CT; lung cancer screening; lung imaging; malignant breast neoplasm; member; practical application; prognostic value; prospective; public health relevance; radiomics; screening; validation studies

 DESCRIPTION (provided by applicant): We propose to establish the Moffitt Imaging Biomarker Validation Center (MIBVAC) focused on imaging biomarker validations for early cancer detection and accurate risk assessments by leveraging our team of strong experts, resources, planned imaging biomarker validation studies, and analysis and network collaboration structures. In previous studies we have demonstrated that various measurements from breast images quantify breast cancer risk. The large cooperative National Lung Screening Trial (NLST) also showed a significant survival improvement for individuals screened by low dose CT compared to those screened with conventional radiography. Additionally, we have recently shown that CT image analysis (radiomics) can improve classification in this data set. However, due to difficulties in obtaining accurate and reproducible measurements and high false-positive rates of current imaging, cancer imaging biomarkers have not been routinely incorporated into clinical risk assessment. If these imaging biomarkers can be accurately tailored at the individual level, their impact will be significantly improved for early cancer detection and intervention. MIBVAC plans to achieve this challenging yet quite achievable goal by rigorously evaluating and validating these imaging biomarkers for rapid translation into clinical and practical applications. We have four specific aims: (Aim 1) Establish breast imaging resources for EDRN both with our existing and new case-control datasets of breast images and to evaluate and validate breast imaging biomarkers based on newly-established case-control dataset of digital breast tomosynthesis (TS) images, (Aim 2) Evaluate and validate lung imaging biomarkers for early detection of cancer first based on NLST low-dose CT (LDCT) cohorts and then expanding with a newly-established case-control cohort of higher resolution LDCT, (Aim 3) Conduct validation studies with imaging biomarkers for EDRN partners and others for other malignancies, and (Aim 4) Refine and validate imaging biomarkers analytically for early detection of breast, lung, and other cancers and to construct MIBVAC imaging data and specimen resources for EDRN collaborations and sharing.

 描述（由申请人提供）：我们建议建立莫菲特成像生物标志物验证中心（MIBVAC），通过利用我们强大的专家团队、资源、计划的成像生物标志物验证研究和分析，专注于早期癌症检测的生物标志物验证和准确的风险评估在之前的研究中，我们已经证明，通过乳房图像的各种测量可以量化乳腺癌风险，大型合作国家肺部筛查试验 (NLST) 也显示，相比之下，低剂量 CT 筛查的个体的生存率显着提高。此外，我们最近表明 CT 图像分析（放射组学）可以改善该数据集的分类，但是，由于难以获得准确且可重复的测量结果以及当前成像的高假阳性率。成像生物标志物尚未常规纳入临床风险评估，如果这些成像生物标志物能够在个体水平上进行精确定制，那么它们对早期癌症检测和干预的影响将显着提高，从而通过严格的方法实现这一具有挑战性但相当可实现的目标。评估和验证这些成像生物标志物，以便快速转化为临床和实际应用：（目标 1）利用我们现有的和新的乳腺图像病例对照数据集为 EDRN 建立乳腺成像资源，并评估和验证乳腺成像生物标志物。基于新建立的数字乳腺断层合成 (TS) 图像病例对照数据集，（目标 2）首先基于 NLST 低剂量 CT (LDCT) 评估和验证肺部成像生物标志物，以早期检测癌症队列，然后利用新建立的更高分辨率 LDCT 病例对照队列进行扩展，（目标 3）对 EDRN 合作伙伴和其他恶性肿瘤的影像生物标志物进行验证研究，以及（目标 4）分析提炼和验证生物标志物以实现早期检测乳腺癌、肺癌和其他癌症的研究，并构建 MIBVAC 成像数据和标本资源以供 EDRN 合作和共享。